Can Paxlovid (nirmatrelvir/ritonavir) cause Gastroesophageal Reflux Disease (GERD)?

Can Paxlovid Cause GERD?

Yes, Paxlovid (nirmatrelvir/ritonavir) can cause gastrointestinal symptoms including those consistent with GERD, with ritonavir being the primary component responsible for these effects. While not specifically labeled as causing GERD, the medication is known to cause various gastrointestinal adverse effects that can manifest as or exacerbate reflux symptoms.

Gastrointestinal Side Effects of Paxlovid

Evidence from Clinical Data

• Ritonavir, a component of Paxlovid, has well-documented gastrointestinal side effects 1:

  • Nausea (9.5% of patients)
  • Vomiting (6.3% of patients)
  • Diarrhea (4.2% of patients)
  • Abdominal discomfort (4.2% of patients)
  • Stomach ache (4.2% of patients)
  • Acute gastritis (reported as serious adverse events leading to drug discontinuation)

• Post-marketing surveillance data shows that gastrointestinal symptoms are among the most common adverse events reported with Paxlovid 2:

  • Dysgeusia (taste disturbance) in 6.05% of cases
  • Diarrhea in 3.04% of cases

Mechanism of Action

The gastrointestinal effects of Paxlovid are primarily attributed to ritonavir, which:

1. Acts as a strong inhibitor of CYP3A4 enzymes and P-glycoprotein transporter proteins 3
2. Has been associated with gastrointestinal adverse events in other contexts, such as HIV treatment, where diarrhea occurs in 10-30% of patients 1

Clinical Implications for GERD Management

Diagnosis Considerations

When a patient on Paxlovid presents with symptoms suggestive of GERD:

1. Recognize temporal relationship: Most adverse effects of Paxlovid occur within days of initiation, with the median onset time being 8 days 2

2. Consider alternative diagnoses: Rule out other causes of similar symptoms:

   • Acute gastritis
   • Medication-induced dyspepsia
   • Functional gastrointestinal disorders

Management Approaches

For patients who develop GERD symptoms while on Paxlovid:

1. Risk-benefit assessment:

   • If COVID-19 symptoms are severe and Paxlovid is deemed necessary, consider symptomatic management of GERD
   • If GERD symptoms are severe or intolerable, discuss alternative COVID-19 treatments

2. Symptomatic management:

   • Antacids for mild symptoms
   • H2-receptor antagonists may provide relief
   • Proton pump inhibitors for more severe symptoms
   • Lifestyle modifications (though these are generally ineffective for medication-induced symptoms) 4

3. Timing considerations:

   • Since Paxlovid is typically prescribed for a short course (5 days), GERD symptoms may be temporary
   • Monitor for resolution of symptoms after completing Paxlovid treatment

Important Caveats

1. Distinction from chronic GERD: Medication-induced reflux symptoms may differ from chronic GERD in presentation and duration

2. Drug interactions: Be cautious when prescribing GERD medications alongside Paxlovid, as ritonavir has significant drug-drug interactions due to its effects on CYP3A enzymes 3

3. Monitoring: Patients with pre-existing GERD may experience worsening of symptoms on Paxlovid and should be monitored more closely

While Paxlovid is not specifically listed as a cause of GERD in major guidelines 5, its documented gastrointestinal adverse effects can produce symptoms consistent with GERD. For patients requiring Paxlovid who develop reflux symptoms, appropriate symptomatic management should be initiated while completing the necessary course of antiviral therapy.